Remgro Says 1: 1 Equity Value Exchange Ratio Envisaged For Mediclinic And Hirslanden
· Issued by Remgro Limited
Remgro Ltd JSE:REM:
JSE: REM - CAUTIONARY: RESTRUCTURING OF INTEREST IN MEDICLINIC HOLDINGS AND SUMMARY OF MEDICLINIC HOLDINGS INTERIM RESULTS
REMGRO: RESTRUCTURING OF INTEREST IN MEDICLINIC HOLDINGS
REMGRO - 1:1 EQUITY VALUE EXCHANGE RATIO ENVISAGED FOR MEDICLINIC AND HIRSLANDEN
REMGRO - HY MEDICLINIC REVENUE INCREASES BY 10% DUE TO VOLUME GROWTH
REMGRO - HY MEDICLINIC ADJUSTED EBITDA INCREASES BY 23%, MARGIN AT 15.5%
Earlier from Remgro
- REM: Headline earnings up 38.6%, dividends and cash flow surged, with strong portfolio performance
- REM: Maziv's ZAR 36bn deal advances with regulatory support, major CapEx, and BEE commitments
- REM: Portfolio now 63% private, with growth led by Mediclinic and CIVH, and focus on performance
- REM: Headline earnings up 38.7%, dividend up 20%, and Heineken Beverages returns to profitability
All Remgro news releases↗
